文献库搜索 | GeneLibs

Wang(SF),Chou(CY),Chao(YW),Chan(TK),Yeh(WY... J Cancer 2025-00-00

...PIK3CA mutation status emerged as a potential CDK4/6i efficacy modifier, particularly among patients who were endocrine ...

Cheng(S),Gomez(CG),Ferrell(M),Giza(R),Syed... Oncologist 2025-07-04

...PIK3CA, downstream effectors of HER2, may confer resistance to HER2 blockade. However, the true incidence of these alter...

Milsap(A),Tsai(J),Jafry(B),Kim(A),Ali Kazm... NPJ Precis Oncol 2025-07-03

...PIK3CA mutations (PIK3CAm) in advanced CRC using plasma-based ctDNA from ~17,000 samples (Guardant360 database). Mutatio...

Basu(S),Sasikumar(S),Sur(S),Vaidya(V),Kheu... Discov Oncol 2025-08-10

...PIK3CA, KRAS, and BRAF activate critical pathways like PI3K/AKT and MAPK/ERK, promoting tumor proliferation and migratio...

Xu(X),Yan(C),Bian(L),Li(Z),Yu(Y),Zhu(X),Ga... Cancer Res 2025-08-15

...PIK3CA) were commonly altered in IM and matched gastric cancer samples in both IGC and DGC, whereas CDH1 mutations were ...

Albayrak(NE) Front Med (Lausanne) 2025-00-00

...PIK3CA mutations and FGFR1 amplification, which can be of therapeutic value. The Ki-67 index, unlike in the pancreas and...

Sabaté-Ortega(J),Ribera-Montserrat(A),Del ... Front Oncol 2025-00-00

...PIK3CA mutation. Although some clinical benefit was achieved, the disease continued to progress. Ultimately, the patient...

Hooda(J),Atkinson(JM),Shah(OS),Yates(M),Br... bioRxiv 2025-08-25

...PIK3CA (57%), CDH1 (57%) and TP53 (57%) among others. Our study confirms and characterizes new ILC PDX models, offering ...

Garg(V),Prokopec(SD),Stone(SC),Pakbaz(S),C... Transl Oncol 2025-11-00

...PIK3CA (33 %), and PPP2R1A (22 %). Copy-number (CN) analysis revealed recurrent amplifications of MYC (67 %), PIK3CA (61...

Kübler(K),Nardone(A),Anand(S),Gurevich(D),... Nat Genet 2025-09-00

...PIK3CA mutations, common in spontaneously arising estrogen-associated de novo uterine cancer, are significantly less fre...